Public Release: 

Oligonucleotide Delivery: Biology, Engineering and Development Conference

An ECI Conference

Engineering Conferences International

Oligonucleotide technologies, such as siRNA, tap into endogenous, highly conserved and specific catalytic mechanisms to efficiently regulate gene expression. As such, they have the potential to enable the development of novel therapeutic options for disease targets previously considered un-druggable by conventional small molecule and biologics means. However, despite the promise, clinical development has been hindered by the challenges encountered by identifying and developing safe and efficacious delivery formulations.

Since its discovery in 1998, RNA silencing has attracted much attention, with over 50,000 peer-reviewed publications, multiple national and international conferences, and significant investment in the biotech and large pharma with the goal of developing new siRNA-based therapies. Despite the interest and investment this has proven to be more difficult that first envisioned. It is widely recognized that there are gaps in our basic understanding on how to best harness this technology for therapeutic use.

The major topics to be discussed are:

Liposomes, nanosomes, polymeric and nano-particulate delivery vehicles
RNA chemical modifications and conjugates to enable delivery
Protein transduction domain as delivery platforms
Mechanisms of cellular uptake and endosomal escape
Biophysical characterization methods
siRNA delivery vehicle toxicology
Local and systemic siRNA delivery case studies

Confirmed Speakers
Achim Aigner, Philipps-University Marburg, Germany
Saghir Akhtar, Kuwait University, Kuwait
Eben Alsberg, Case Western Reserve University, USA
Dan Anderson, MIT, USA
Tomohiro Asai, University of Shizuoka, Japan
Himanshu Brahmbhatt, EnGeneIC Ltd, Australia
Bob Brown, Dicerna, USA
Kenneth Clark, GlaxoSmithKline, UK
Pieter Cullis, University of British Columbia, Canada
Mark E. Davis, California Institute of Technology, USA
Derek M. Dykxhoorm, University of Miami Miller School of Medicine, USA
Xavier de Mollerat Du Jeu, Life Technologies, USA
Omid Farokhzad, Harvard Medical School, USA
Elena Feinstein, Quark Pharma, Israel / USA
Mauro Ferrari, The Methodist Hospital Research Institute, USA
Mercedes González-Juarrero, Colorado State University, USA
Tatsuhiro Ishida, The University of Tokushima, Japan
Rudy Juliano, University of North Carolina Chapel Hill, USA
Jan Kamps, University of Groningen, The Netherlands
Kazunori Kataoka, University of Tokyo, Japan
Jørgen Kjems, Århus University, Denmark
Troels Koch, Santaris Pharma A/S, Denmark / USA
Ülo Langel, Stockholm University, Sweden
Gabriel López-Berestein, The University of Texas MD Anderson Cancer Center, USA
Zheng-Rong Lu, Case Western Reserve University, USA
Jennifer MacDiarmid, EnGeneIC Ltd, Australia
Ram I. Mahato, University of Tennessee Health Science Center, USA
Muthiah Manoharan, Alnylam Pharmaceuticals, USA
Nigel A.J. McMillan, Diamantina Institute, University of Queensland, Australia X
in Ming, University of North Carolina Chapel Hill, USA
Tamara Minko, Rutgers University, USA
Andrés Montefeltro, nLife Therapeutics, Spain
Sterghios Moschos, University of Westminster, UK
Deborah Palliser, Albert Einstein School of Medicine, USA
Dan Peer, Tel Aviv University, Israel
Jean Phillipe Pellois, Texas A&M University, USA
Blake Peterson, The University of Kansas, USA
Tariq M. Rana, Sanford-Burnham Medical Research Institute, USA
Steven L. Regen, Lehigh University, USA
John Rossi, City of Hope, Duarte, USA
Dmitry Samarsky, RiboBio, China
Ansgar Santel, Silence Therapeutics AG, Germany
Alan D. Schreiber, ZaBeCor Pharmaceuticals, Inc., USA
Sabine Schreidler, Sanofi-Aventis, Germany
Georg Sczakiel, University of Lübeck, Germany
Peter H. Seeberger, Max Planck Institute of Colloids and Interfaces, Berlin, Germany
Rita Serda, Methodist Hospital Research Institute, USA
Mouldy Sioud, Norwegian Radium Hospital, Norway
Anil Sood, MD Anderson Cancer Center, USA
Janos Szebeni, Semmelweis University, Budapest, Hungary
C. Shad Thaxton, Northwestern University, USA
Ernst Wagner, Ludwig-Maximilians-Universitat, Munchen, Germany
Roberto Weinmann, Sylentis, Spain
Johannes Winkler, University of Vienna, Austria
You-Yeon Won, Purdue University, USA
Matthew Wood, Oxford University, UK
Miqin Zhang, University of Washington, USA

###

Submission of Abstracts

ABSTRACT SUBMISSION IS NOW OPEN

Abstracts of approximately 300 words should be submitted as soon as possible and no later than June 15, 2012 to be considered for an oral presentation and June 30, 2012 for poster presentations. The abstract should include both significance of the research as well as results that will be discussed in order to allow a scientific assessment of the work by the organizers. Abstracts should be submitted electronically following the instructions given in On-line Abstract Submission. If unable to submit the abstract electronically, please contact the ECI (info@engconfintl.org).

Only a limited number of oral presentation slots are available and thus all submissions for oral presentation will be considered for both oral and poster presentation.

A poster competition among graduate student submissions is planned.

Engineering Conferences International (ECI) is a global engineering conferences program, originally established in 1962, that provides opportunities for the exploration of problems and issues of concern to engineers and scientists from many disciplines.

The format of the weeklong research conference provides morning and late afternoon or evening sessions in which major presentations are made. Available time is included during the afternoons for ad hoc meetings, informal discussions, and/or recreation. This format is designed to enhance rapport among participants and promote dialogue on the development of the meeting. We believe that the conferences have been instrumental in generating ideas and disseminating information to a greater extent than is possible through more conventional forums.

All participants are expected both to attend the entire conference and to contribute actively to the discussions. The recording/photographing of lectures and presentations is forbidden. As ECI conferences take place in an informal atmosphere, casual clothing is the usual attire.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.